{
    "nctId": "NCT00570323",
    "briefTitle": "Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer",
    "officialTitle": "A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 72,
    "primaryOutcomeMeasure": "Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All subjects must be female.\n* Postmenopausal status, defined as any one of the following criteria:\n\n  * Documented history of bilateral oophorectomy.\n  * Age 60 years or more.\n  * Age 45 to 59 and satisfying one or more of the following criteria:\n\n    * Amenorrhea for at least 12 months and intact uterus.\n    * Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range including: patients who have had a hysterectomy and patients who have received hormone replacement.\n* Patients must have histologically confirmed invasive breast cancer with a primary tumor of 3 cm or more in greatest dimension as measured by clinical examination.\n* Estrogen receptor and/or progesterone receptor positive disease.\n* Patients must not have received any prior treatment for current or newly diagnosed breast cancer.\n* Patients must have not received previous treatment with any of the study medications or similar drugs.\n* No use of selective estrogen receptor modulators (SERM) such as raloxifene or similar agents in the past 2 years.\n* WHO performance status of 0, 1, or 2.\n* Adequate organ function defined as follows:\n\n  * Adequate renal function, defined by a serum creatinine within 3 times the upper limits of normal.\n  * Adequate liver function, defined by total bilirubin, AST, ALT, and alkaline phosphatase within 3 times the upper limits of normal.\n  * Adequate bone marrow function, defined as a WBC greater than 3.0 ml, PLT greater than 75,000/ul, Hb greater than 9 gm/l.\n* Willing to undergo breast core biopsies as required by the study protocol. - Ability to understand and sign a written informed consent for participation in the trial.\n* Life expectancy of at least 1 year.\n\nExclusion Criteria:\n\n* Premenopausal status.\n* Other coexisting malignancies with the exception of basal cell carcinoma or cervical cancer in situ.\n* Patients with brain metastasis.\n* WHO performance status of 3 or 4.\n* Is judged by the investigator, uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the clinical trial. - Concurrent treatment with estrogens or progestins. Patients must stop these drugs at least two weeks prior to study entry.\n* Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.\n* Platelet count less than 75,000.\n* In the opinion of the investigator, bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections.\n* History of hypersensitivity to castor oil.\n* Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded) - Patients with recurrent breast cancer.\n* Patients with contralateral second primary breast cancers are eligible.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}